Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
AstraZeneca
Farmers Insurance
Queensland Health
Cerilliant
Boehringer Ingelheim
Healthtrust
Mallinckrodt
Harvard Business School

Generated: May 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,795,238

« Back to Dashboard

Which drugs does patent 7,795,238 protect, and when does it expire?

Patent 7,795,238 protects TYZEKA and is included in two NDAs.

This patent has forty-four patent family members in twenty countries.
Summary for Patent: 7,795,238
Title:.beta.-L-2'-deoxy-nucleosides for the treatment of hepatitis B
Abstract:This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2'-deoxy-.beta.-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2'-deoxy-.beta.-L-erythro-pentofuranonucleoside has the formula: ##STR00001## wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2'-deoxy-.beta.-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2'-deoxy-.beta.-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.
Inventor(s): Gosselin; Gilles (Montpellier, FR), Imbach; Jean-Louis (Montpellier, FR), Bryant; Martin L. (Carlisle, MA)
Assignee: Idenix Pharmaceuticals, Inc. (Cambridge, MA) Centre National de la Recherche Scientifique (Paris, FR) L'Universite Montpellier II (Montpellier, FR)
Application Number:11/929,798
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 7,795,238

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novartis TYZEKA telbivudine SOLUTION;ORAL 022154-001 Apr 28, 2009 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS ➤ Try a Free Trial
Novartis TYZEKA telbivudine TABLET;ORAL 022011-001 Oct 25, 2006 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,795,238

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,304,043 .beta.-L-2'-deoxy-nucleosides for the treatment of hepatitis B ➤ Try a Free Trial
6,444,652 .beta.-L-2'-deoxy-nucleosides for the treatment of hepatitis B ➤ Try a Free Trial
2,011,195,922 ➤ Try a Free Trial
6,946,450 .beta.-L-2'-deoxy-nucleosides for the treatment of hepatitis B ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 7,795,238

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 313550 ➤ Try a Free Trial
Australia 5475799 ➤ Try a Free Trial
Brazil 9912896 ➤ Try a Free Trial
Brazil PI9912896 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Colorcon
Farmers Insurance
McKinsey
Julphar
Teva
Baxter
Harvard Business School
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.